| $385M | ||
| $350M | ||
| $215M | ||
| $94M | ||
| $82M | ||
| $62M |
Buys | $0 | 0 | 0 |
Sells | $670,812 | 1 | 100 |
| Garner Ebun | General Counsel & Corp. Sec. | 0 | $0 | 1 | $670,812 | $-670,812 |
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Erasca, Inc. have bought $0 and sold $670,812 worth of Erasca, Inc. stock.
On average, over the past 5 years, insiders at Erasca, Inc. have bought $6.78M and sold $2.21M worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 80,000 shares for transaction amount of $181,920 was made by Casdin Alexander W. (director) on 2024‑05‑21.
| 2026-01-07 | Sale | Garner Ebun | General Counsel & Corp. Sec. | 120,000 0.0604% | $5.59 | $670,812 | +70.99% | |
| 2024-05-21 | Casdin Alexander W. | director | 80,000 0.0447% | $2.27 | $181,920 | +7.23% | ||
| 2023-12-06 | Lim Jonathan E | Chairman & CEO | 278,150 0.1825% | $1.72 | $478,418 | +35.84% | ||
| 2023-12-06 | Start Valerie Denise Harding | director | 10,000 0.007% | $1.85 | $18,480 | +35.84% | ||
| 2023-12-05 | Lim Jonathan E | Chairman & CEO | 721,850 0.4606% | $1.69 | $1.22M | +34.29% | ||
| 2023-12-04 | Casdin Alexander W. | director | 30,000 0.0197% | $1.66 | $49,785 | +39.88% | ||
| 2023-10-05 | Lim Jonathan E | Chairman & CEO | 1M 0.695% | $2.03 | $2.03M | +4.25% | ||
| 2023-06-08 | Lim Jonathan E | Chairman & CEO | 100,000 0.0676% | $2.75 | $275,000 | -18.38% | ||
| 2023-04-10 | Casdin Alexander W. | director | 20,000 0.0135% | $2.76 | $55,230 | -14.44% | ||
| 2023-03-28 | Lim Jonathan E | Chairman & CEO | 100,000 0.0693% | $2.84 | $284,000 | -12.41% | ||
| 2023-01-10 | Lim Jonathan E | Chairman & CEO | 60,000 0.0413% | $3.86 | $231,420 | -29.33% | ||
| 2022-12-21 | Bristol James Arthur | director | 20,000 0.0162% | $4.14 | $82,800 | -35.48% | ||
| 2022-12-21 | Start Valerie Denise Harding | director | 10,000 0.0091% | $4.64 | $46,400 | -35.48% | ||
| 2022-12-15 | Casdin Alexander W. | director | 20,000 0.0167% | $4.87 | $97,490 | -42.77% | ||
| 2022-12-14 | Lim Jonathan E | Chairman & CEO | 40,000 0.0338% | $4.99 | $199,600 | -43.49% | ||
| 2022-12-13 | Chen Bihua | director | 307,692 0.3325% | $6.50 | $2M | -44.42% | ||
| 2021-08-10 | Chen Bihua | director | 200,000 0.2202% | $22.10 | $4.42M | -41.38% | ||
| 2021-07-26 | Sale | Chen Bihua | director | 200,000 0.2009% | $18.77 | $3.75M | -35.23% | |
| 2021-07-20 | Chen Bihua | director | 950,000 0.7974% | $16.00 | $15.2M | -35.39% | ||
| 2021-07-20 | Multani Pratik S | director | 6,200 0.0052% | $16.00 | $99,200 | -35.39% |
| Garner Ebun | General Counsel & Corp. Sec. | 25076 0.0088% | $249,756.96 | 1 | 1 | <0.0001% |
| Lim Jonathan E | Chairman & CEO | 12899360 4.5466% | $128.48M | 7 | 0 | <0.0001% |
| Chen Bihua | director | 10813246 3.8113% | $107.7M | 3 | 1 | <0.0001% |
| Casdin Alexander W. | director | 573974 0.2023% | $5.72M | 4 | 0 | <0.0001% |
| Multani Pratik S | director | 172866 0.0609% | $1.72M | 1 | 0 | <0.0001% |
| Start Valerie Denise Harding | director | 20000 0.007% | $199,200.00 | 3 | 0 | <0.0001% |
| Bristol James Arthur | director | 20000 0.007% | $199,200.00 | 1 | 0 | <0.0001% |
| Hambleton Julie | director | 6000 0.0021% | $59,760.00 | 1 | 0 | <0.0001% |
$11,588,217 | 69 | 42.07% | $2.9B | |
$47,419,530 | 58 | 17.20% | $2.22B | |
$11,583,737 | 45 | 49.75% | $2.63B | |
$571,084,134 | 44 | 4.33% | $2.23B | |
$62,927,079 | 29 | 14.02% | $2.28B | |
$61,703,557 | 26 | 40.25% | $3.09B | |
$7,033,101 | 22 | -12.19% | $2.37B | |
Erasca, Inc. (ERAS) | $27,105,902 | 21 | -16.06% | $2.83B |
$174,105,409 | 15 | 10.88% | $2.75B | |
$73,814,940 | 15 | -4.77% | $2.67B | |
$92,580,864 | 14 | -1.28% | $3.03B | |
$45,445,266 | 9 | -24.96% | $3.05B | |
$130,038,539 | 8 | 26.82% | $2.46B | |
$32,575,266 | 8 | 37.03% | $2.9B | |
$91,589,325 | 7 | -6.97% | $2.91B | |
$4,623,072 | 7 | 11.07% | $2.34B | |
$24,000,085 | 4 | 33.26% | $2.88B | |
$142,493,653 | 3 | 4.30% | $3.09B | |
$5,000,000 | 1 | -22.84% | $2.83B |
| Increased Positions | 62 | +39.49% | 7M | +3.42% |
| Decreased Positions | 59 | -37.58% | 11M | -4.85% |
| New Positions | 19 | New | 771,271 | New |
| Sold Out Positions | 15 | Sold Out | 4M | Sold Out |
| Total Postitions | 160 | +1.91% | 215M | -1.42% |
| Frazier Life Sciences Management, L.P. | $81,599.00 | 8% | 22.73M | 0 | 0% | 2025-09-30 |
| T. Rowe Price Investment Management, Inc. | $72,633.00 | 7.12% | 20.23M | -100,255 | -0.49% | 2025-09-30 |
| Vr Adviser, Llc | $64,107.00 | 6.29% | 17.86M | 0 | 0% | 2025-09-30 |
| Logos Global Management Lp | $54,389.00 | 5.34% | 15.15M | +150,000 | +1% | 2025-09-30 |
| Blackrock, Inc. | $54,106.00 | 5.31% | 15.07M | -94,879 | -0.63% | 2025-09-30 |
| Suvretta Capital Management, Llc | $52,062.00 | 5.11% | 14.5M | 0 | 0% | 2025-09-30 |
| Paradigm Biocapital Advisors Lp | $48,680.00 | 4.78% | 13.56M | +2M | +13.88% | 2025-09-30 |
| Vanguard Group Inc | $45,994.00 | 4.51% | 12.81M | +116,235 | +0.92% | 2025-09-30 |
| Arch Venture Management, Llc | $39,689.00 | 3.89% | 11.06M | 0 | 0% | 2025-09-30 |
| Vivo Capital, Llc | $33,292.00 | 3.27% | 9.27M | +3M | +37.25% | 2025-09-30 |